Drug intelligence / Profile preview

AZT-101

Development stage: Phase 2
Lead developer: AZTherapies
Modality: Small Molecules
Administration: Inhalation

Overview

**AZT-101** is an inhaled formulation of cromolyn sodium developed by AZTherapies for neurological indications. Cromolyn sodium is a mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and cytokines from mast cells, thereby targeting neuroinflammation. AZTherapies is evaluating it as part of the combination therapy ALZT-OP1a (cromolyn sodium + sildenafil) in Phase 2 trials for post-ischemic stroke cognitive impairment (PSCI).[8]

Other names: inhaled cromolyn sodium

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on AZT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZT-101.

Explore the full profile